Skip to Content
Merck
  • Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.

Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.

European journal of pediatrics (2014-09-25)
Yuki Ogawa, Mitsuru Irikura, Yuka Kobaru, Mayu Tomiyasu, Yoshie Kochiyama, Mamiko Uriu, Yoichi Ishitsuka, Yuki Kondo, Eiji Yukawa, Noboru Kamada, Hitoshi Ohno, Toshio Yamazaki, Tetsumi Irie
ABSTRACT

This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated that clearance of doxapram (CL; L/kg/h) was affected by postmenstrual age (PMA; weeks), body weight (BW; g), and aspartate aminotransferase (AST; IU/L). In addition, the volume of distribution (Vd; L/kg) was affected by gestational age (GA; weeks). The final pharmacokinetic model was as follows: CL = BW / PMA × 0.0453 × serum AST(-0.373); Vd = 2.54 (if GA >28 weeks) and Vd = 2.54 × 2.11 (if GA ≤28 weeks). The interindividual variabilities in CL and Vd were 39.9 and 83.0 %, respectively, and the residual variability was 20.9 %. To clarify the reasons for large interindividual variations, the enzymes involved in the metabolic pathway of doxapram were also determined. We found that doxapram was metabolized by CYP3A4/5. We report the population pharmacokinetics of doxapram in neonates and the involvement of CYP3A4/5 in its metabolism. The final model of population pharmacokinetics may be useful for formulating a safe and effective dosage regimen and for predicting serum doxapram concentrations in neonates.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Quinidine sulfate salt dihydrate
USP
Montelukast sodium, United States Pharmacopeia (USP) Reference Standard
Montelukast sodium, European Pharmacopoeia (EP) Reference Standard
Supelco
Montelukast Sodium, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
trans-2-Phenylcyclopropylamine hydrochloride, 97%
Sigma-Aldrich
trans-2-Phenylcyclopropylamine hydrochloride
Sigma-Aldrich
4-Methylpyrazole hydrochloride, alcohol dehydrogenase inhibitor
Sigma-Aldrich
1-Aminobenzotriazole
Sigma-Aldrich
Sulfaphenazole, ≥98%
Sigma-Aldrich
Ketoconazole, 99.0-101.0% (EP, titration)
Ketoconazole, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ketoconazole
Quinidine sulfate, European Pharmacopoeia (EP) Reference Standard
Supelco
Ketoconazole, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ketoconazole, United States Pharmacopeia (USP) Reference Standard